Literature DB >> 25492975

Reduced CSF hypocretin-1 levels are associated with cluster headache.

Mads Barloese1, Poul Jennum2, Nunu Lund1, Stine Knudsen3, Steen Gammeltoft4, Rigmor Jensen5.   

Abstract

BACKGROUND: Cluster headache (CH) is a debilitating disorder characterized by unilateral, severe pain attacks with accompanying autonomic symptoms, often waking the patient from sleep. As it exhibits strong chronobiological traits and genetic studies have suggested a link with the hypocretin (HCRT) system, the objective of this study was to investigate HCRT-1 in CH patients.
METHODS: Cerebrospinal fluid HCRT-1 concentration was measured in 12 chronic and 14 episodic CH patients during an active bout, and in 27 healthy controls. The patients were well characterized and clinical features compared to the HCRT concentration.
RESULTS: We found significantly lower HCRT levels both in chronic (p = 0.0221) and episodic CH (p = 0.0005) patients compared with controls. No significant relationship was found with other clinical features.
CONCLUSIONS: This is the first report of significantly reduced HCRT concentrations in CH patients. We speculate that decreased HCRT may reflect insufficient antinociceptive activity of the hypothalamus. The mechanism of the antinociceptive effect of HCRT is not known and requires further investigation. This study supports the hypothesis of a connection between arousal regulation and CH. © International Headache Society 2014.

Entities:  

Keywords:  Cluster headache; hypocretin; hypothalamus; pain; sleep disorders

Mesh:

Substances:

Year:  2014        PMID: 25492975     DOI: 10.1177/0333102414562971

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  11 in total

Review 1.  Emerging relevance of circadian rhythms in headaches and neuropathic pain.

Authors:  Mark J Burish; Zheng Chen; Seung-Hee Yoo
Journal:  Acta Physiol (Oxf)       Date:  2018-07-25       Impact factor: 6.311

2.  Hypothalamic regulation of headache and migraine.

Authors:  Arne May; Rami Burstein
Journal:  Cephalalgia       Date:  2019-08-29       Impact factor: 6.292

Review 3.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

Review 4.  The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications.

Authors:  Mads C J Barloese
Journal:  Clin Auton Res       Date:  2017-09-23       Impact factor: 4.435

Review 5.  Neurobiology and sleep disorders in cluster headache.

Authors:  Mads Christian Johannes Barloese
Journal:  J Headache Pain       Date:  2015-08-20       Impact factor: 7.277

6.  Identifying a gene expression signature of cluster headache in blood.

Authors:  Else Eising; Nadine Pelzer; Lisanne S Vijfhuizen; Boukje de Vries; Michel D Ferrari; Peter A C 't Hoen; Gisela M Terwindt; Arn M J M van den Maagdenberg
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

7.  Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort.

Authors:  Caroline Ran; Carmen Fourier; Julia M Michalska; Anna Steinberg; Christina Sjöstrand; Elisabet Waldenlind; Andrea Carmine Belin
Journal:  J Headache Pain       Date:  2017-08-22       Impact factor: 7.277

Review 8.  Therapeutic Approaches for the Management of Trigeminal Autonomic Cephalalgias.

Authors:  Diana Y Wei; Rigmor H Jensen
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

9.  No Association Between G1246A Polymorphism in HCRTR2 Gene and Risk of Cluster Headache: Evidence From an Updated Meta-Analysis of Observational Studies.

Authors:  Jiao Yang; Si-Yi Yu; Jie Yang; Jing Kong; Fan-Rong Liang; Zheng-Tao Lv
Journal:  Front Genet       Date:  2020-12-03       Impact factor: 4.599

Review 10.  Molecular factors in migraine.

Authors:  Marta Kowalska; Michał Prendecki; Wojciech Kozubski; Margarita Lianeri; Jolanta Dorszewska
Journal:  Oncotarget       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.